• Citer

Phase I1 study of vindesine in disseminated squamous cell carcinoma of the uterine cervix: An EORTC gynecological cancer cooperative group study

par Vermorken, Jan Baptist;Landoni, Fabio;Pecorelli, Sërgio;Piccart-Gebhart, Martine ;van der Burg, Maria;ten Bokkel Huinink, Wim;George, Michael;Greggi, Stefano;Rotmensz, Nicole
Référence International journal of gynecological cancer, 1, 6, page (248-252)
Publication Publié, 1991

Article révisé par les pairs

• Détails
• Contenu

Résumé :

Vermorken JB, Landoni F, Pecorelli S, Piccart MJ, van der Burg MEL, ten Bokkel Huinink WW, George M, Greggi S, Rotmensz N. Phase I1 study of vindesine in disseminated squamous cell carcinoma of the uterine cervix: an EORTC Gynecological Cancer Cooperative Group study. Int Gynecol Cancer 1991; 1: 248-252. Twenty-nine patients with disseminated squamous cell carcinoma of the uterine cervix were treated with a 3 mg/m2 weekly i.v. bolus schedule of vindesine for 6 weeks (thereafter every 2 weeks). Twenty-seven patients were evaluable for response, 19 of whom had received prior chemotherapy (14 also vincristine). Five of the 27 patients (19%) showed a partial response, all being part of the 22 patients with only distant metastases. No objective response were observed among five patients who also had loco-regional recurrent disease. The median duration of response was 21 (11-58) weeks. Dose-limiting toxic effects were leukopenia and peripheral neuropathy. Vindesine warrants further study in combination chemotherapy protocols for cervical cancer. © 1991 Blackwell Science Ltd.